期刊文献+

白细胞介素与支架内再狭窄

Interleukins and in-stent restenosis
原文传递
导出
摘要 支架置入术后的支架内再狭窄是困扰动脉粥样硬化性心脑血管病微侵袭介入治疗发展的主要问题。支架置入术后的血管内炎症反应是再狭窄的重要原因之一。其中,以白细胞介素为代表的细胞因子起着复杂和多变的作用。文章综述了白细胞介素表达水平对血管内皮增生的作用以及对支架内再狭窄发生率的影响。 In-stent restenosis after stenting is a major problem to perplex the minimaJly invasive interventional treatment and development in atherosclerotic cardio-cerebrovascular diseases. Intravascular inflammatory response is one of the important causes for restenosis after stenting, in which as represented by interleukins, the cytokines play complex and variable roles. This article reviews the effects of the expression levels of interleukins on vascular endothelial hyperplasia and the incidence of in-stent restenosis.
出处 《国际脑血管病杂志》 北大核心 2012年第11期870-874,共5页 International Journal of Cerebrovascular Diseases
关键词 白细胞介素类 支架 血管成形术 复发 生物学标记 炎症介导素类 炎症 Interleukins Stents Angioplasty Recurrence Biological Markers Inflanarmtion Mediators Inflarrrnation
  • 相关文献

参考文献2

二级参考文献31

  • 1Babapulle MN,Joseph L,Belisle P,Brophy JM,Eisenberg MJ.A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.Lancet 2004; 364:583-591.
  • 2Forrester JS,Fishbein M,Helfant R,Fagin J.A paradigm for restenosis based on cell biology:clues for the development of new preventive therapies.J Am Coll Cardiol 1991; 17:758-769.
  • 3Kornowski R,Hong MK,Tio FO,Bramwell O,Wu H,Leon MB.Instent restenosis:contributions of inflammatory responses and arterial injury to neointimal hyperplasia.J Am Coll Cardiol 1998; 31:224-230.
  • 4Welt FG,Rogers C.Inflammation and restenosis in the stent era.Arterioscler Thromb Vasc Biol 2002; 22:1769-1776.
  • 5Nuhrenberg TC,Voisard R,Fahlisch F,Rudelius M,Braun J,Gschwend J,et al.Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty.FASEB J 2005; 19:246-248.
  • 6Mause SF,von Hundelshausen P,Zernecke A,Koenen RR,Weber C.Platelet microparticles:a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.Arterioscler Thromb Vasc Biol 2005; 25:1512-1518.
  • 7Morice MC,Colombo A,Meier B,Serruys P,Tamburino C,Guagliumi G,et al; REALITY Trial Investigators.Sirolimusvs paclitaxel-eluting stents in de novo coronary artery lesions.the REALITY trial:a randomized controlled trial.JAMA 2006;295:895-904.
  • 8Goy JJ,Stauffer JC,Siegenthaler M,Beno(i)t A,Seydoux C.A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology:The TAXi Trial.J Am Coll Cardiol 2005; 45:308-311.
  • 9Windecker S,Remondino A,Eberli FR,Jüni P,R(a)ber L,Wenaweser P,et al.Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.N Eng J Med 2005; 353:653-622.
  • 10Donners MM,Daemen MJ,Cleutjens KB,Heeneman S.Inflammation and restenosis:implication for therapy.Ann Med 2003; 35:523-553.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部